Search

Message from the EHA Board

After more than a decade of tireless work to further EHA’s mission our Executive Director, Carin Smand, has unfortunately announced that she will be leaving our organization.

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

Lighting the Flame Journal Club

A learning and connecting hematology experience led by alumni of the Lighting the Flame program. The Lighting the Flame Journal Club is an online group that's open to all members of the Lighting the Flame community.

Read more

EHA-Balkan Hematology Tutorial on Lymphoid Malignancies

“EHA and the Albanian Association of Hematology have jointly decided to postpone the first EHA-Balkan Hematology Tutorial in response to a request from the Albanian government to limit all international meetings.

Read more

Madrid Declaration: joint call for action on training requirements

The Madrid Declaration on enhanced training requirements for hematologists in the Professional Qualifications Directive enjoyed broad support from national society representatives at the EHA22 National Societies Dinner in Madrid.

Read more

EHA and EBMT joint meeting on CAR T cells, first of its kind in Europe

The European Hematology Association (EHA) and European Society for Blood and Marrow Transplantation (EBMT) will hold the first European CAR T Cell Meeting together in Paris on February 14-16, 2019.

Read more

Killer antibodies against AML

Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.

Read more